Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.75 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.59 |
| ▸ | PIM1 | P11309 | 7/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328498 | 0.90 | FYN (0.76) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4338216 | 0.89 | FYN (0.74) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4333823 | 0.88 | FYN (0.71) | FYNTGFBR2PIK3CGPIM1ACVR2A | |
| SCHEMBL4557669 | 0.88 | FYN (0.78) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4335168 | 0.87 | FYN (0.77) | FYNTGFBR2PIK3CGPIM1VCP | |
| SCHEMBL4333198 | 0.86 | FYN (1.00) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4340607 | 0.84 | PIK3CG (0.73) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4336109 | 0.84 | FYN (0.71) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4335564 | 0.84 | FYN (0.60) | FYNTGFBR2PIK3CGPIM1PIM2 | |
| SCHEMBL4335453 | 0.84 | FYN (0.82) | FYNTGFBR2PIK3CGPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007147647-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | FYN 151/4885TGFBR2 2444/4885PIK3CG 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.